{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T17:29:32Z","timestamp":1788715772878,"version":"build-2803163510"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2020,5,3]],"date-time":"2020-05-03T00:00:00Z","timestamp":1588464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","award":["RIA2018EF-083"],"award-info":[{"award-number":["RIA2018EF-083"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Remdesivir has received significant attention for its potential application in the treatment of COVID-19, caused by SARS-CoV-2. Remdesivir has already been tested for Ebola virus disease treatment and found to have activity against SARS and MERS coronaviruses. The remdesivir core contains GS-441524, which interferes with RNA-dependent RNA polymerases alone. In non-human primates, following IV administration, remdesivir is rapidly distributed into PBMCs and converted within 2\u2009h to the active nucleoside triphosphate form, while GS-441524 is detectable in plasma for up to 24\u2009h. Nevertheless, remdesivir pharmacokinetics and pharmacodynamics in humans are still unexplored, highlighting the need for a precise analytical method for remdesivir and GS-441524 quantification.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The validation of a reliable UHPLC-MS\/MS method for remdesivir and GS-441524 quantification in human plasma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Remdesivir and GS-441524 standards and quality controls were prepared in plasma from healthy donors. Sample preparation consisted of protein precipitation, followed by dilution and injection into the QSight 220 UHPLC-MS\/MS system. Chromatographic separation was obtained through an Acquity HSS T3 1.8\u2009\u03bcm, 2.1\u205f\u00d7\u205f50\u2009mm column, with a gradient of water and acetonitrile with 0.05% formic acid. The method was validated using EMA and FDA guidelines.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Analyte stability has been evaluated and described in detail. The method successfully fulfilled the validation process and it was demonstrated that, when possible, sample thermal inactivation could be a good choice in order to improve biosafety.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This method represents a useful tool for studying remdesivir and GS-441524 clinical pharmacokinetics, particularly during the current COVID-19 outbreak.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaa152","type":"journal-article","created":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T11:10:15Z","timestamp":1585653015000},"page":"1772-1777","source":"Crossref","is-referenced-by-count":91,"title":["Development and validation of a UHPLC-MS\/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2\/COVID-19 and Ebola virus disease"],"prefix":"10.1093","volume":"75","author":[{"given":"Valeria","family":"Avataneo","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Pharmacology and Pharmacogenetics, Amedeo di Savoia Hospital, Department of Medical Sciences, University of Turin, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5973-9948","authenticated-orcid":false,"given":"Amedeo","family":"de Nicol\u00f2","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Pharmacology and Pharmacogenetics, Amedeo di Savoia Hospital, Department of Medical Sciences, University of Turin, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1977-9694","authenticated-orcid":false,"given":"Jessica","family":"Cusato","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Pharmacology and Pharmacogenetics, Amedeo di Savoia Hospital, Department of Medical Sciences, University of Turin, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Antonucci","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Pharmacology and Pharmacogenetics, Amedeo di Savoia Hospital, Department of Medical Sciences, University of Turin, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Manca","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Pharmacology and Pharmacogenetics, Amedeo di Savoia Hospital, Department of Medical Sciences, University of Turin, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Palermiti","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Pharmacology and Pharmacogenetics, Amedeo di Savoia Hospital, Department of Medical Sciences, University of Turin, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona","family":"Waitt","sequence":"first","affiliation":[{"name":"Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK"},{"name":"Infectious Diseases Institute, Makerere University College of Health Sciences, P.O. Box 22418, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Walimbwa","sequence":"first","affiliation":[{"name":"Infectious Diseases Institute, Makerere University College of Health Sciences, P.O. Box 22418, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Lamorde","sequence":"first","affiliation":[{"name":"Infectious Diseases Institute, Makerere University College of Health Sciences, P.O. Box 22418, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"di Perri","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Pharmacology and Pharmacogenetics, Amedeo di Savoia Hospital, Department of Medical Sciences, University of Turin, Turin, Italy"},{"name":"CoQua Lab, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"D\u2019Avolio","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Pharmacology and Pharmacogenetics, Amedeo di Savoia Hospital, Department of Medical Sciences, University of Turin, Turin, Italy"},{"name":"CoQua Lab, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,5,3]]},"reference":[{"key":"2020061904542552600_dkaa152-B1","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"2020061904542552600_dkaa152-B2","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1021\/acs.jmedchem.6b01594","article-title":"Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses","volume":"60","author":"Siegel","year":"2017","journal-title":"J Med Chem"},{"key":"2020061904542552600_dkaa152-B3","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40506-017-0130-z","article-title":"Discovering drugs for the treatment of Ebola virus","volume":"9","author":"Bixler","year":"2017","journal-title":"Curr Treat Options Infect Dis"},{"key":"2020061904542552600_dkaa152-B4","year":"2016"},{"key":"2020061904542552600_dkaa152-B5","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci Transl Med"},{"key":"2020061904542552600_dkaa152-B6","doi-asserted-by":"crossref","first-page":"e00221","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease","volume":"9","author":"Agostini","year":"2018","journal-title":"mBio"},{"key":"2020061904542552600_dkaa152-B7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5582\/bst.2020.01020","article-title":"Drug treatment options for the 2019-new coronavirus (2019-nCoV)","volume":"14","author":"Lu","year":"2020","journal-title":"Biosci Trends"},{"key":"2020061904542552600_dkaa152-B8","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/cbic.202000047","article-title":"Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV","volume":"21","author":"Liu","year":"2020","journal-title":"Chembiochem"},{"key":"2020061904542552600_dkaa152-B9","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"2020061904542552600_dkaa152-B10","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1517\/14740331003767395","article-title":"Therapeutic drug monitoring in highly active antiretroviral therapy","volume":"9","author":"Liu","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"2020061904542552600_dkaa152-B11","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2165\/00003495-200363080-00002","article-title":"Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs?","volume":"63","author":"Aarnoutse","year":"2003","journal-title":"Drugs"},{"key":"2020061904542552600_dkaa152-B12","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1080\/17512433.2016.1235972","article-title":"Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients","volume":"9","author":"Punyawudho","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2020061904542552600_dkaa152-B13","year":"2018"},{"key":"2020061904542552600_dkaa152-B14","year":"2013"},{"key":"2020061904542552600_dkaa152-B15","year":"2011"},{"key":"2020061904542552600_dkaa152-B16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1373\/clinchem.2015.238626","article-title":"CLSI C62-A: a new standard for clinical mass spectrometry","volume":"62","author":"Lynch","year":"2016","journal-title":"Clin Chem"},{"key":"2020061904542552600_dkaa152-B17","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.clinbiochem.2004.11.007","article-title":"Matrix effects: the Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometry","volume":"38","author":"Taylor","year":"2005","journal-title":"Clin Biochem"},{"key":"2020061904542552600_dkaa152-B18","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.4155\/bio-2017-0059","article-title":"Matrix effect management in liquid chromatography mass spectrometry: the internal standard normalized matrix effect","volume":"9","author":"De Nicol\u00f2","year":"2017","journal-title":"Bioanalysis"},{"key":"2020061904542552600_dkaa152-B19","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jpba.2017.05.018","article-title":"UHPLC-MS\/MS method with sample dilution to test therapeutic adherence through quantification of ten antihypertensive drugs in urine samples","volume":"142","author":"De Nicol\u00f2","year":"2017","journal-title":"J Pharm Biomed Anal"},{"key":"2020061904542552600_dkaa152-B20","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jpba.2018.12.040","article-title":"LC-MS application for therapeutic drug monitoring in alternative matrices","volume":"166","author":"Avataneo","year":"2019","journal-title":"J Pharm Biomed Anal"},{"key":"2020061904542552600_dkaa152-B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00430-004-0219-0","article-title":"Stability and inactivation of SARS coronavirus","volume":"194","author":"Rabenau","year":"2005","journal-title":"Med Microbiol Immunol"},{"key":"2020061904542552600_dkaa152-B22","doi-asserted-by":"crossref","first-page":"e0126864","DOI":"10.1371\/journal.pone.0126864","article-title":"Contribution of disulfide bridges to the thermostability of a type A feruloyl esterase from Aspergillus usamii","volume":"10","author":"Yin","year":"2015","journal-title":"PLoS One"},{"key":"2020061904542552600_dkaa152-B23","doi-asserted-by":"crossref","first-page":"12471","DOI":"10.1038\/s41598-017-12748-y","article-title":"Evaluation of irreversible protein thermal inactivation caused by breakage of disulphide bonds using methanethiosulphonate","volume":"7","author":"Futami","year":"2017","journal-title":"Sci Rep"},{"key":"2020061904542552600_dkaa152-B24","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N Engl J Med"},{"key":"2020061904542552600_dkaa152-B25","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jchromb.2008.10.021","article-title":"Major pitfalls in the measurement of artemisinin derivatives in plasma in clinical studies","volume":"876","author":"Lindegardh","year":"2008","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2020061904542552600_dkaa152-B26","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jpba.2012.03.030","article-title":"Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients","volume":"66","author":"D\u2019Avolio","year":"2012","journal-title":"J Pharm Biomed Anal"},{"key":"2020061904542552600_dkaa152-B27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jpba.2013.11.027","article-title":"Development and validation of a useful UPLC-MS\/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients","volume":"90","author":"Agnesod","year":"2014","journal-title":"J Pharm Biomed Anal"},{"key":"2020061904542552600_dkaa152-B28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jpba.2015.10.017","article-title":"UHPLC-MS\/MS method with automated on-line solid phase extraction for the quantification of entecavir in peripheral blood mononuclear cells of HBV+ patients","volume":"118","author":"De Nicolo","year":"2016","journal-title":"J Pharm Biomed Anal"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/7\/1772\/33405111\/dkaa152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/7\/1772\/33405111\/dkaa152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T08:56:09Z","timestamp":1592556969000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/75\/7\/1772\/5828362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,3]]},"references-count":28,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,5,3]]},"published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa152","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,7]]},"published":{"date-parts":[[2020,5,3]]}}}